, Volume 16, Issue 4, pp 459–464 | Cite as

Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications

  • Thomas J. Wilson
  • Erin L. McKean
  • Ariel L. Barkan
  • William F. Chandler
  • Stephen E. Sullivan


Reported biochemical remission rates following surgical intervention for acromegaly range from 38 to 83 %. In patients not achieving surgical remission, few options remain, mostly limited to medical management and radiation therapy. There is debate over whether or not to offer reoperation to patients in whom surgical remission is not achieved with initial resection. Retrospective chart review was undertaken to determine all patients having acromegaly with persistently elevated GH and/or IGF-1 levels after initial pituitary adenoma resection, and who underwent reoperation using endoscopic endonasal approach at a single institution. Biochemical remission was defined as a postoperative GH level <1 ng/mL and a normal postoperative IGF-1 level in the absence of any medical therapy. In total, 14 patients underwent repeat surgical intervention for acromegaly via endoscopic transsphenoidal approach. Of the 14 patients, 8 (57 %) achieved biochemical remission following repeat surgical intervention. Lower preoperative GH levels were associated with greater chance of biochemical remission (P = 0.048). New endocrinopathies were seen in 2 patients (14 %), and both were transient diabetes insipidus. Meningitis occurred in 2 patients (14 %); both were aseptic meningitis with no sequelae. No mortality was encountered. Repeat surgical intervention for acromegaly via endoscopic transsphenoidal approach appears safe and effective. With no mortality and minimal morbidity, repeat surgical intervention via endoscopic transsphenoidal approach appears a reasonable option for these hard-to-treat patients and should be considered for patients in whom surgical remission is not achieved with initial surgery.


Acromegaly Endoscopic endonasal Pituitary 


Conflict of interest

The authors have no conflicts of interest to report pertaining to the materials or methods used in this study or the findings specified in this paper.


  1. 1.
    Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89–95. doi: 10.1530/EJE-08-0267 PubMedCrossRefGoogle Scholar
  2. 2.
    Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93:61–67. doi: 10.1210/jc.2007-1191 PubMedCrossRefGoogle Scholar
  3. 3.
    Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141–3148. doi: 10.1210/jc.2009-2670 PubMedCrossRefGoogle Scholar
  4. 4.
    Ludecke DK, Abe T (2006) Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 83:230–239. doi: 10.1159/000095533 PubMedCrossRefGoogle Scholar
  5. 5.
    Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152:379–387. doi: 10.1530/eje.1.01863 PubMedCrossRefGoogle Scholar
  6. 6.
    De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF (2003) Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88:3567–3572PubMedCrossRefGoogle Scholar
  7. 7.
    Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 58:86–91CrossRefGoogle Scholar
  8. 8.
    Shimon I, Cohen ZR, Ram Z, Hadani M (2001) Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48:1239–1245PubMedGoogle Scholar
  9. 9.
    Hofstetter CP, Mannaa RH, Mubita L, Anand VK, Kennedy JW, Dehdashti AR, Schwartz TH (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29:E6. doi: 10.3171/2010.7.FOCUS10173 PubMedCrossRefGoogle Scholar
  10. 10.
    Gondim JA, Almeida JP, de Albuquerque LA, Gomes E, Schops M, Ferraz T (2010) Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus 29:E7. doi: 10.3171/2010.7.FOCUS10167 PubMedCrossRefGoogle Scholar
  11. 11.
    Yano S, Kawano T, Kudo M, Makino K, Nakamura H, Kai Y, Morioka M, Kuratsu J (2009) Endoscopic endonasal transsphenoidal approach through the bilateral nostrils for pituitary adenomas. Neurol Med Chir (Tokyo) 49:1–7CrossRefGoogle Scholar
  12. 12.
    Jane JA Jr, Starke RM, Elzoghby MA, Reames DL, Payne SC, Thorner MO, Marshall JC, Laws ER Jr, Vance ML (2011) Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 96:2732–2740. doi: 10.1210/jc.2011-0554 PubMedCrossRefGoogle Scholar
  13. 13.
    Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB (2001) Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86:1645–1652PubMedCrossRefGoogle Scholar
  14. 14.
    Tabaee A, Anand VK, Barron Y, Hiltzik DH, Brown SM, Kacker A, Mazumdar M, Schwartz TH (2009) Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg 111:545–554. doi: 10.3171/2007.12.17635 PubMedCrossRefGoogle Scholar
  15. 15.
    Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–618PubMedCrossRefGoogle Scholar
  16. 16.
    Marko NF, Lasota E, Hamrahian AH, Weil RJ (2012) Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg 117:522–538. doi: 10.3171/2012.4.JNS11739 PubMedCrossRefGoogle Scholar
  17. 17.
    Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM (1997) Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187–3191PubMedCrossRefGoogle Scholar
  18. 18.
    Powell JS, Wardlaw SL, Post KD, Freda PU (2000) Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 85:2068–2071PubMedCrossRefGoogle Scholar
  19. 19.
    Biermasz NR, van Dulken H, Roelfsema F (2000) Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 85:2476–2482PubMedCrossRefGoogle Scholar
  20. 20.
    Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J (2000) Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 85:3779–3785PubMedCrossRefGoogle Scholar
  21. 21.
    Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S, Attanasio R (2001) Failure of radiotherapy in acromegaly. Eur J Endocrinol 145:717–726PubMedCrossRefGoogle Scholar
  22. 22.
    Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA (2006) Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91:1239–1245. doi: 10.1210/jc.2005-1616 PubMedCrossRefGoogle Scholar
  23. 23.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2007) Treatment of acromegaly: is there still a place for radiotherapy? Pituitary 10:53–59. doi: 10.1007/s11102-007-0002-5 PubMedCrossRefGoogle Scholar
  24. 24.
    Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T, Takakura K (2000) Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 93(Suppl 3):19–22. doi: 10.3171/jns.2000.93.supplement3.0019 PubMedGoogle Scholar
  25. 25.
    Zhang N, Pan L, Wang EM, Dai JZ, Wang BJ, Cai PW (2000) Radiosurgery for growth hormone-producing pituitary adenomas. J Neurosurg 93(Suppl 3):6–9. doi: 10.3171/jns.2000.93.supplement3.0006 PubMedGoogle Scholar
  26. 26.
    Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M (2003) Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 88:3105–3112PubMedCrossRefGoogle Scholar
  27. 27.
    Castinetti F, Taieb D, Kuhn JM, Chanson P, Tamura M, Jaquet P, Conte-Devolx B, Regis J, Dufour H, Brue T (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 90:4483–4488. doi: 10.1210/jc.2005-0311 PubMedCrossRefGoogle Scholar
  28. 28.
    Jezkova J, Marek J, Hana V, Krsek M, Weiss V, Vladyka V, Lisak R, Vymazal J, Pecen L (2006) Gamma knife radiosurgery for acromegaly–long-term experience. Clin Endocrinol (Oxf) 64:588–595. doi: 10.1111/j.1365-2265.2006.02513.x CrossRefGoogle Scholar
  29. 29.
    Pollock BE, Jacob JT, Brown PD, Nippoldt TB (2007) Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. J Neurosurg 106:833–838. doi: 10.3171/jns.2007.106.5.833 PubMedCrossRefGoogle Scholar
  30. 30.
    Vik-Mo EO, Oksnes M, Pedersen PH, Wentzel-Larsen T, Rodahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M (2007) Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 157:255–263. doi: 10.1530/EJE-07-0189 PubMedCrossRefGoogle Scholar
  31. 31.
    Losa M, Gioia L, Picozzi P, Franzin A, Valle M, Giovanelli M, Mortini P (2008) The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab 93:2546–2552. doi: 10.1210/jc.2008-0135 PubMedCrossRefGoogle Scholar
  32. 32.
    Sheehan JP, Pouratian N, Steiner L, Laws ER, Vance ML (2011) Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 114:303–309. doi: 10.3171/2010.5.JNS091635 PubMedCrossRefGoogle Scholar
  33. 33.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577–584PubMedCrossRefGoogle Scholar
  34. 34.
    Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99–104PubMedCrossRefGoogle Scholar
  35. 35.
    Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60:734–740. doi: 10.1111/j.1365-2265.2004.02045.x Google Scholar
  36. 36.
    Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:209–214. doi: 10.1111/j.1365-2265.2006.02450.x CrossRefGoogle Scholar
  37. 37.
    Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69:299–305. doi: 10.1111/j.1365-2265.2008.03208.x CrossRefGoogle Scholar
  38. 38.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034–3040PubMedCrossRefGoogle Scholar
  39. 39.
    Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779–2786PubMedCrossRefGoogle Scholar
  40. 40.
    Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JA, Wardlaw JM (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554–4563PubMedCrossRefGoogle Scholar
  41. 41.
    Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP (2004) Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res 62:227–232. doi: 10.1159/000081418 PubMedCrossRefGoogle Scholar
  42. 42.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168–175. doi: 10.1111/j.1365-2265.2005.02317.x CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Thomas J. Wilson
    • 1
  • Erin L. McKean
    • 1
  • Ariel L. Barkan
    • 1
  • William F. Chandler
    • 1
  • Stephen E. Sullivan
    • 1
  1. 1.Department of NeurosurgeryUniversity of MichiganAnn ArborUSA

Personalised recommendations